Hepatitis C Newsletter
Clinical Trials, Cohort Studies, Pilot Studies 1 - 9
Basic and Applied Science, Pre-Clinical Studies 9 - 11
HIV/HCV Coinfection 12 - 17
Complementary and alternative medicine 18
Epidemiology, Diagnostics & Miscellaneous Works 18 - 21
Liver Cancer 21 - 24
Psychosocial correlates of alcohol use and reduction for individuals with hepatitis C.
Perzynski AT, McCormick R, Webster NJ, et al. J Stud Alcohol Drugs. 2011 Sep;72(5):787-98.
Occult HCV or delayed viral clearance from lymphocytes of Chronic HCV genotype 3 patients after interferon therapy. Muazzam AG, Qureshi S, Mansoor A, et al. Genet Vaccines Ther. 2011 Sep 6;9(1):14. [Epub ahead of print]
Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients with Chronic HCV infection. Zeuzem S, Asselah T, Angus P, et al. Gastroenterology. 2011 Sep 14. [Epub ahead of print]
Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response.
Floreani A, Cazzagon N, Boemo DG, et al. Eur J Gastroenterol Hepatol. 2011 Sep 12. [Epub ahead of print]
Response-guided telaprevir combination treatment for hepatitis C virus infection. Sherman KE, Flamm SL, Afdhal NH, et al. N Engl J Med. 2011 Sep 15;365(11):1014-24.
Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R. Ann Intern Med. 2011 Sep 20;155(6):353-60.
Low risk for hepatitis C seroconversion in methadone maintenance treatment. Peles E, Schreiber S, Rados V, Adelson M. J Addict Med. 2011 Sep;5(3):214-20.
Impact of Hispanic or Asian Ethnicity on the Treatment Outcomes of Chronic Hepatitis C: Results From the WIN-R Trial. Hu KQ, Freilich B, Brown RS, Brass C, Jacobson IM. J Clin Gastroenterol. 2011 Sep;45(8):720-6.
Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: Final results of APPROACH (A Prospective study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada). Myers RP, Cooper C, Sherman M, et al. Can J Gastroenterol. 2011 Sep;25(9):503-10.
Association of hepatitis C virus infection and malnutrition-inflammation complex syn-drome in maintenance hemodialysis patients. Tsai HB, Chen PC, Liu CH, et al. Nephrol Dial Transplant. 2011 Sep 5. [Epub ahead of print]
Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+ T-cells. Arends JE, Hoepelman AI, Nanlohy NM, et al. Apoptosis. 2011 Sep;16(9):959-66. doi: 10.1007/s10495-011-0620-2.
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon -alpha based therapy in HCV type-1 infection. Weich V, Herrmann E, Chung TL, et al. J Gastroenterol. 2011 Sep 13. [Epub ahead of print]
Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. Shoeb D, Rowe IA, Freshwater D, et al. Eur J Gastroenterol Hepatol. 2011 Sep;23(9):747-53.
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. Sinn DH, Kim YJ, Lee ST, et al. J Gastroenterol Hepatol. 2011 Sep;26(9):1374-9. doi: 10.1111/j.1440-1746.2011.06744.x.
Alteration of hepatic nuclear receptor-mediated signaling pathways in HCV patients with and without a history of alcohol drinking. Wu C, Gilroy R, Taylor R, et al. Hepatology. 2011 Sep 2. doi: 10.1002/hep.24645. [Epub ahead of print]
T-lymphocyte subsets in peripheral blood and liver tissue of patients with chronic hepatitis B and C. Dimitropoulou D, Karakantza M, Tsamandas AC, et al. In Vivo. 2011 Sep-Oct;25(5):833-40.
Prohibitin is overexpressed in Huh-7-HCV and Huh-7.5-HCV cells harboring in vitro transcribed full-length hepatitis C virus RNA. Dang SS, Sun MZ, Yang E, et al. Virol J. 2011 Sep 6;8(1):424. [Epub ahead of print]
Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene. Toyoda H, Kumada T, Hayashi K, et al. J Med Virol. 2011 Sep;83(9):1559-64. doi: 10.1002/jmv.22145.
Cell-to-Cell Contact with Hepatitis C Virus-Infected Cells Reduces Functional Capacity of Natural Killer Cells. Yoon JC, Lim JB, Park JH, Lee JM. J Virol. 2011 Sep 21. [Epub ahead of print]
Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination. Winnock M, Bani-Sadr F, Pambrun E, et al . Vaccine. 2011 Sep 12. [Epub ahead of print]
Hip bone geometry in HIV/HCV-co-infected men and healthy controls. Walker Harris V, Sutcliffe CG, Araujo AB, et al. Osteoporos Int. 2011 Sep 8. [Epub ahead of print]
Clinical variables identify seronegative HCV co-infection in HIV-infected individuals.
Bharti AR, Letendre SL, Wolfson T, et al. J Clin Virol. 2011 Sep 14. [Epub ahead of print]
Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration. Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G. J Clin Virol. 2011 Sep 14. [Epub ahead of print]
HIV and hepatitis C coinfection: pathogenesis: microbial translocation. Page EE, Nelson M, Kelleher P. Curr Opin HIV AIDS. 2011 Sep 13. [Epub ahead of print]
HIV-1 co-infection and morphine co-exposure severely dysregulate HCV-induced hepatic pro-inflammatory cytokine release and free radical production: increased pathogenesis coincides with uncoordinated host-defenses. El-Hage N, Dever SM, Fitting S, Ahmed T, Hauser KF. J Virol. 2011 Sep 7. [Epub ahead of print]
Management of end-stage liver disease in HIV/hepatitis C virus co-infection. Spengler U. Curr Opin HIV AIDS. 2011 Sep 13. [Epub ahead of print]
Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. Vivithanaporn P, Nelles K, Deblock L, Newman SC, Gill MJ, Power C. J Neurol Sci. 2011 Sep 17. [Epub ahead of print]
The Impact of Hepatitis C Coinfection on Kidney Disease Related to Human Immuno-deficiency Virus (HIV): A Biopsy Study. George E, Nadkarni GN, Estrella MM, et al. Medicine (Baltimore). 2011 Sep;90(5):289-95.
The role of insulin resistance in HIV/hepatitis C virus-coinfected patients. Eslam M, López-Cortés LF, Romero-Gomez M. Curr Opin HIV AIDS. 2011 Sep 20. [Epub ahead of print]
Alterations in Immune Function are Associated with Liver Enzyme Elevation in HIV and HCV Co-infection after Commencement of Combination Antiretroviral Therapy. Cameron BA, Emerson CR, Workman C, Kelly MD, Lloyd AR, Post JJ. J Clin Immunol. 2011 Sep 20. [Epub ahead of print]
The effect of hepatitis C treatment and HIV coinfection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Matser A, Urbanus A, Geskus R, et al. Addiction. 2011 Sep 15. doi: 10.1111/j.1360-0443.2011.03654.x. [Epub ahead of print]
In vitro antiviral activities of extracts derived from Daucus maritimus seeds. Miladi S, Abid N, Debarnôt C, et al. Nat Prod Res. 2011 Sep 6. [Epub ahead of print]
Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection. Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE. J Clin Gastroenterol. 2011 Sep 19. [Epub ahead of print]
Public Health Implications of Rapid Hepatitis C Screening With an Oral Swab for Community-Based Organizations Serving High-Risk Populations. Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Am J Public Health. 2011 Sep 22. [Epub ahead of print]
The cost-effectiveness of HCV antiviral treatment for injecting drug user populations. Martin NK, Vickerman P, Miners A, et al. Hepatology. 2011 Sep 2. doi: 10.1002/hep.24656. [Epub ahead of print]
Comparison of 8 diagnostic algorithms for liver fibrosis in hepatitis C: New algorithms are more precise and entirely non-invasive. Boursier J, de Ledinghen V, Zarski JP, et al. Hepatology. 2011 Sep 2. doi: 10.1002/hep.24654. [Epub ahead of print]
Fast DNA and protein microarray tests for the diagnosis of hepatitis C virus infection on a single platform. Ember SW, Schulze H, Ross AJ, et al. Anal Bioanal Chem. 2011 Sep 1. [Epub ahead of print]
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*.
Hatzakis A, Wait S, Bruix J, et al. J Viral Hepat. 2011 Sep;18 Suppl 1:1-16. doi: 10.1111/j.1365-2893.2011.01499.x.
Factors affecting prognosis of small hepatocellular carcinoma in Taiwanese patients follow-ing hepatic resection. Ko CJ, Chien SY, Chou CT, Chen LS, Chen ML, Chen YL. Can J Gastroenterol. 2011 Sep;25(9):485-91.
Tumor-related factors do not influence the prognosis of solitary hepatocellular carcinoma after partial hepatectomy. Kobayashi T, Itamoto T, Tashiro H, et al. J Hepatobiliary Pancreat Sci. 2011 Sep;18(5):689-99.
Hepatitis C Virus-Induced Cancer Stem Cell-like Signatures in Cell Culture and Murine Tumor Xenografts. Ali N, Allam H, May R, et al. J Virol. 2011 Sep 21. [Epub ahead of print]
Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C. Sterling RK, Wright EC, Morgan TR, et al. Am J Gastroenterol. 2011 Sep 20. doi: 10.1038/ajg.2011.312. [Epub ahead of print]
Hepatocellular carcinoma in HIV hepatitis C virus. Puoti M, Rossotti R, Garlaschelli A, Bruno R. Curr Opin HIV AIDS. 2011 Sep 20. [Epub ahead of print]
The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma. Zhang X, Ryu SH, Xu Y, et al. J Clin Virol. 2011 Sep 16. [Epub ahead of print]